Market Summary
USD12.48-0.09
Market Closedas of 22 Sep 2023, 09:44 am-0.72%
MDRX Stock Price
MDRX RSI Chart
MDRX Valuation
MDRX Price/Sales (Trailing)
MDRX Profitability
MDRX Fundamentals
MDRX Revenue
MDRX Earnings
Price Action
52 Week Range
11.3019.77
(Low)(High)
Last 7 days
0.8%
Last 30 days
-2.5%
Last 90 days
10.7%
Trailing 12 Months
-24.1%
MDRX Financial Health
MDRX Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for MDRX
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-03 | Vakharia Tejal | sold (taxes) | -16,535 | 13.52 | -1,223 | svp general counsel |
2023-08-04 | Poulton Richard J. | acquired | - | - | 366,302 | ceo |
2023-08-04 | Poulton Richard J. | back to issuer | -2,190,660 | 13.5 | -162,271 | ceo |
2023-05-25 | Hammond Lisa | sold (taxes) | -18,060 | 11.89 | -1,519 | svp & chief hr officer |
2023-05-10 | Poulton Richard J. | sold (taxes) | -157,140 | 11.9 | -13,205 | ceo |
2023-05-10 | Hammond Lisa | sold (taxes) | -28,000 | 11.9 | -2,353 | svp & chief hr officer |
2023-05-10 | Vakharia Tejal | sold (taxes) | -37,711 | 11.9 | -3,169 | svp general counsel |
2023-05-02 | Langan Thomas | sold (taxes) | -22,999 | 12.15 | -1,893 | president and cco |
2023-05-02 | Jones Leah | sold (taxes) | -27,009 | 12.15 | -2,223 | chief financial officer |
2023-05-01 | Jones Leah | sold (taxes) | -86,031 | 12.53 | -6,866 | chief financial officer |
Which funds bought or sold MDRX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | reduced | -40.42 | -451,170 | 611,100 | 0.01% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 72.39 | 34,506 | 86,108 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 5.72 | 10,000 | 454,000 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.96 | -111,999 | 1,663,770 | -% |
2023-08-16 | Nuveen Asset Management, LLC | reduced | -34.67 | -6,387,720 | 10,911,300 | -% |
2023-08-15 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | added | 0.51 | -47,000 | 1,554,000 | 0.01% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | added | 0.31 | -69,961 | 2,150,000 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 6.22 | 187,585 | 7,528,910 | -% |
2023-08-15 | CAPTRUST FINANCIAL ADVISORS | reduced | -9.91 | -28,714 | 191,948 | -% |
2023-08-15 | Belpointe Asset Management LLC | sold off | -100 | -10,610 | - | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Allscripts Healthcare Solutions
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 10, 2023 | dimensional fund advisors lp | 8.5% | 9,277,320 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 12.40% | 13,550,569 | SC 13G/A | |
| Jan 26, 2023 | blackrock inc. | 19.1% | 20,902,942 | SC 13G/A | |
| Jan 20, 2023 | blackrock inc. | 19.1% | 20,902,942 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 10.82% | 13,268,135 | SC 13G/A | |
| Feb 08, 2022 | dimensional fund advisors lp | 8.2% | 10,090,569 | SC 13G/A | |
| Jan 28, 2022 | blackrock inc. | 19.5% | 23,846,502 | SC 13G/A | |
| Apr 12, 2021 | wellington management group llp | 3.78% | 5,292,953 | SC 13G/A | |
| Feb 12, 2021 | dimensional fund advisors lp | 6.9% | 10,939,535 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 10.11% | 15,973,325 | SC 13G/A |
Recent SEC filings of Allscripts Healthcare Solutions
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 18, 2023 | 8-K | Current Report | |
| Sep 05, 2023 | 4 | Insider Trading | |
| Aug 18, 2023 | 8-K | Current Report | |
| Aug 10, 2023 | NT 10-Q | NT 10-Q | |
| Aug 08, 2023 | 4 | Insider Trading | |
| Jun 14, 2023 | 8-K | Current Report |
Peers (Alternatives to Allscripts Healthcare Solutions)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
UNH | 464.6B | 348.5B | 1.79% | -1.49% | 22.01 | 1.33 | 13.69% | 15.63% |
VEEV | 32.5B | 2.2B | 8.51% | 21.82% | 60.14 | 14.55 | 11.56% | 37.20% |
| MID-CAP | ||||||||
TDOC | 3.2B | 2.5B | -15.42% | -33.04% | -0.79 | 1.26 | 13.30% | 59.30% |
OMCL | 2.3B | 1.2B | -11.37% | -43.78% | -99.56 | 1.87 | -1.77% | -138.27% |
| SMALL-CAP | ||||||||
NXGN | 1.6B | 678.1M | 44.50% | 39.22% | 673.28 | 2.34 | 12.34% | 2970.73% |
MDRX | 1.4B | - | -2.48% | -24.09% | 22.47 | 1.63 | - | - |
PHR | 968.3M | 319.4M | -31.51% | -31.01% | -6.35 | 3.03 | 30.27% | 15.64% |
CCRN | 865.4M | 2.4B | -1.69% | -15.70% | 6.96 | 0.36 | -5.09% | -42.39% |
SLP | 797.7M | 55.7M | -11.73% | -21.76% | 76.79 | 14.33 | 7.05% | -12.17% |
HSTM | 657.9M | 274.0M | 1.13% | -2.46% | 51.11 | 2.4 | 5.60% | 81.56% |
HCAT | 559.2M | 284.6M | -15.76% | -1.49% | -3.8 | 1.96 | 7.33% | -1.68% |
CPSI | 215.3M | 336.9M | -12.06% | -46.54% | 43.71 | 0.64 | 10.57% | -74.53% |
Allscripts Healthcare Solutions News
Returns for MDRX
Cumulative Returns on MDRX
-1.6%
10-Year Cumulative Returns
-0.9%
7-Year Cumulative Returns
-2.6%
5-Year Cumulative Returns
16.6%
3-Year Cumulative Returns
Risks for MDRX
What is the probability of a big loss on MDRX?
91.5%
Probability that Allscripts Healthcare Solutions stock will be more than 20% underwater in next one year
64.6%
Probability that Allscripts Healthcare Solutions stock will be more than 30% underwater in next one year.
27.3%
Probability that Allscripts Healthcare Solutions stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does MDRX drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Allscripts Healthcare Solutions was unfortunately bought at previous high price.
Drawdowns
Financials for Allscripts Healthcare Solutions
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 |
| Revenue | 0.9% | 837 | 830 | 820 | 811 | 806 | 1,027 | 1,255 | 1,503 | 1,531 | 1,573 | 1,615 | 1,633 | 1,661 | 1,685 | 1,715 | 1,750 | 1,744 | 1,680 | 1,588 | 1,498 | 1,487 |
| Cost Of Revenue | -0.7% | 874 | 881 | 882 | 883 | 444 | 599 | 758 | 937 | 973 | 1,003 | 1,023 | 1,022 | 1,015 | 1,010 | 1,026 | 1,025 | 1,031 | 983 | 915 | 865 | 844 |
| Gross Profit | 2.2% | 655 | 641 | 630 | 620 | 362 | 427 | 497 | 566 | 557 | 571 | 592 | 610 | 646 | 675 | 690 | 725 | 713 | 697 | 673 | 633 | 643 |
| S&GA Expenses | 1.4% | 360 | 355 | 323 | 314 | 181 | 248 | 329 | 390 | 404 | 407 | 398 | 401 | 393 | 405 | 427 | 451 | 474 | 460 | 428 | 401 | 393 |
| R&D Expenses | 1.3% | 201 | 198 | 196 | 194 | 117 | 142 | 167 | 206 | 212 | 227 | 242 | 245 | 251 | 253 | 266 | 268 | 271 | 254 | 222 | 202 | 182 |
| EBITDA | -0.4% | 300 | 301 | 164 | 202 | 12.00 | -26.62 | -30.78 | -61.81 | -17.17 | -10.81 | -143 | -116 | -100 | - | - | - | - | - | - | - | - |
| EBITDA Margin | -1.2% | 0.36* | 0.36* | 0.16* | 0.16* | 0.01* | -0.02* | -0.02* | -0.04* | -0.01* | -0.01* | -0.08* | -0.07* | -0.06* | - | - | - | - | - | - | - | - |
| Interest Expenses | -21.4% | 9.00 | 11.00 | 12.00 | 13.00 | 16.00 | 19.00 | 27.00 | 34.00 | 39.00 | 44.00 | 44.00 | 43.00 | 45.00 | 48.00 | 49.00 | 51.00 | 49.00 | 45.00 | 41.00 | 38.00 | 51.00 |
| Earnings Before Taxes | -2.1% | 122 | 125 | 160 | 162 | -11.57 | -57.10 | -106 | -149 | -138 | -145 | -294 | -281 | -258 | -246 | 14.00 | 13.00 | 21.00 | 22.00 | -209 | -190 | -169 |
| EBT Margin | 2.1% | 0.15* | 0.14* | 0.15* | 0.13* | -0.02* | -0.05* | -0.05* | -0.08* | -0.06* | -0.06* | -0.14* | -0.12* | -0.12* | - | - | - | - | - | - | - | - |
| Net Income | -2.7% | 61.00 | 62.00 | 148 | 134 | 775 | 759 | 730 | 700 | -46.39 | -52.65 | -194 | -182 | 222 | 204 | 428 | 408 | 37.00 | 43.00 | -174 | -154 | -166 |
| Net Income Margin | -3.5% | 0.07* | 0.08* | 0.14* | 0.11* | 0.61* | 0.59* | 0.47* | 0.43* | -0.03* | -0.03* | -0.11* | -0.10* | 0.13* | - | - | - | - | - | - | - | - |
| Free Cashflow | -14.9% | 155 | 182 | -16.16 | -80.72 | -332 | -337 | -114 | -123 | 73.00 | 55.00 | 22.00 | 30.00 | 2.00 | - | - | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 |
| Assets | -1.4% | 1,691 | 1,714 | 2,430 | 2,425 | 2,484 | 2,540 | 2,871 | 2,918 | 3,146 | 3,189 | 3,253 | 3,206 | 3,230 | 3,235 | 3,242 | 3,181 | 4,518 | 4,354 | 4,370 | 4,230 | 3,883 |
| Current Assets | -2.2% | 811 | 829 | 1,541 | 761 | 805 | 841 | 1,135 | 1,153 | 949 | 870 | 907 | 841 | 774 | 804 | 834 | 859 | 844 | 856 | 911 | 857 | 668 |
| Cash Equivalents | -1.5% | 493 | 500 | 83.00 | 133 | 142 | 160 | 454 | 531 | 219 | 199 | 204 | 130 | 129 | 139 | 137 | 174 | 91.00 | 114 | 112 | 131 | 104 |
| Net PPE | -21.8% | 12.00 | 15.00 | 9.00 | 10.00 | 54.00 | 59.00 | 67.00 | 72.00 | 70.00 | 76.00 | 82.00 | 88.00 | 97.00 | 106 | 116 | 122 | 160 | 161 | 165 | 135 | 165 |
| Goodwill | 0.0% | 524 | 524 | 520 | 507 | 974 | 975 | 975 | 975 | 1,287 | 1,361 | 1,361 | 974 | 1,387 | 1,382 | 1,374 | 986 | 2,208 | 100 | 2,051 | 1,293 | 61.00 |
| Liabilities | -0.8% | 514 | 518 | 1,077 | 1,017 | 1,066 | 1,147 | 1,193 | 1,251 | 1,938 | 1,946 | 2,011 | 1,921 | 1,949 | 1,919 | 1,786 | 1,601 | 2,933 | 2,756 | 2,816 | 2,639 | 2,316 |
| Current Liabilities | -1.3% | 253 | 256 | 647 | 547 | 567 | 596 | 880 | 935 | 745 | 1,111 | 1,158 | 1,211 | 1,177 | 880 | 800 | 798 | 894 | 907 | 889 | 890 | 684 |
| LT Debt, Current | - | - | - | - | - | - | - | - | - | 48.00 | 375 | 371 | 364 | 359 | 22.00 | 21.00 | 20.00 | 20.00 | 20.00 | 20.00 | 28.00 | 25.00 |
| LT Debt, Non Current | 0.2% | 200 | 200 | 377 | 350 | 373 | 421 | 169 | 168 | 1,026 | 662 | 680 | 551 | 555 | 823 | 766 | 648 | 1,002 | 983 | 1,064 | 907 | 747 |
| Shareholder's Equity | -1.6% | 1,177 | 1,196 | 1,353 | 1,408 | 1,419 | 1,393 | 1,679 | 1,666 | 1,208 | 1,243 | 1,242 | 1,285 | 1,281 | 1,316 | 1,456 | 1,580 | 1,117 | 1,142 | 1,110 | 1,160 | 1,105 |
| Retained Earnings | 2.0% | 753 | 739 | 803 | 13.00 | 680 | 664 | 642 | 633 | -94.71 | -95.25 | -87.64 | -49.34 | -30.37 | -24.64 | 125 | 133 | -251 | -228 | -319 | -338 | -354 |
| Additional Paid-In Capital | 0.0% | 1,924 | 1,924 | 1,922 | 1,962 | 1,952 | 1,904 | 1,907 | 1,903 | 1,929 | 1,921 | 1,915 | 1,907 | 1,876 | 1,868 | 1,858 | 1,881 | 1,765 | 1,767 | 1,771 | 1,781 | 1,782 |
| Shares Outstanding | -1.4% | 109 | 111 | 115 | 116 | 123 | 125 | 141 | 140 | 158 | 163 | 162 | 162 | 163 | 167 | 166 | 171 | 175 | 175 | 178 | 181 | 181 |
| Minority Interest | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.00 | 29.00 | 29.00 | 38.00 | 39.00 | 41.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 |
| Cashflow From Operations | -14.7% | 161 | 189 | -10.74 | -75.43 | -319 | -322 | -98.43 | -106 | 84.00 | 67.00 | 37.00 | 46.00 | 20.00 | -0.56 | 15.00 | 68.00 | 188 | 237 | 262 | 279 | 257 |
| Share Based Compensation | 1.2% | 46.00 | 46.00 | 39.00 | 35.00 | 17.00 | 22.00 | 27.00 | 34.00 | 35.00 | 34.00 | 37.00 | 39.00 | 38.00 | 39.00 | 36.00 | 35.00 | 34.00 | 35.00 | 39.00 | 37.00 | 36.00 |
| Cashflow From Investing | 1.7% | 646 | 635 | -37.38 | -12.17 | 1,625 | 1,621 | 1,631 | 1,615 | -95.70 | -124 | -162 | -161 | 351 | 191 | 364 | 248 | -439 | -331 | -510 | -412 | -309 |
| Cashflow From Financing | 2.2% | -520 | -532 | -314 | -258 | -1,315 | -1,274 | -1,230 | -1,109 | 97.00 | 114 | 190 | 67.00 | -352 | -182 | -375 | -292 | 262 | 147 | 287 | 199 | 85.00 |
| Buy Backs | 13.4% | 286 | 252 | 467 | 417 | 589 | 634 | 325 | 335 | 65.00 | 56.00 | 56.00 | 111 | 139 | 102 | 146 | 139 | 102 | 102 | 70.00 | 12.00 | 62.00 |
MDRX Income Statement
2022-09-30CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
| Revenue: | ||||
| Revenue from contract with customers | $ 151,922 | $ 144,668 | $ 445,492 | $ 419,526 |
| Cost of revenue: | ||||
| Total cost of revenue | 68,486 | 75,028 | 209,093 | 218,550 |
| Gross profit | 83,436 | 69,640 | 236,399 | 200,976 |
| Selling, general and administrative expenses | 32,518 | 27,392 | 133,683 | 87,680 |
| Research and development | 23,681 | 21,042 | 69,851 | 62,644 |
| Asset impairment charges | 0 | 359 | 0 | 531 |
| Amortization of intangible and acquisition-related assets | 2,236 | 2,363 | 6,648 | 7,090 |
| Income from operations | 25,001 | 18,484 | 26,217 | 43,031 |
| Interest expense | (1,246) | (3,617) | (5,269) | (9,709) |
| Other income, net | 1,655 | 4,493 | 3,800 | 21,819 |
| Gain on sale of businesses, net | 0 | 8,363 | 0 | 8,363 |
| Equity in net loss income of unconsolidated investments | (617) | (257) | (1,222) | (321) |
| Income from continuing operations before income taxes | 24,793 | 27,466 | 23,526 | 63,183 |
| Income tax (provision) benefit | (13,868) | (7,190) | 9,132 | (12,464) |
| Income from continuing operations, net of tax | 10,925 | 20,276 | 32,658 | 50,719 |
| Income (loss) from discontinued operations | (434) | (6,187) | (9,252) | (6,545) |
| Gain on sale of discontinued operations | 5,174 | 0 | 7,939 | 647 |
| Income tax effect on discontinued operations | (1,137) | 2,091 | (57,986) | 2,342 |
| Income (loss) from discontinued operations, net of tax | 3,603 | (4,096) | (59,299) | (3,556) |
| Net income (loss) | $ 14,528 | $ 16,180 | $ (26,641) | $ 47,163 |
| Basic | ||||
| Continuing operations | $ 0.10 | $ 0.16 | $ 0.29 | $ 0.38 |
| Discontinued operations | 0.03 | (0.03) | (0.52) | (0.03) |
| Net earnings (loss) per Common Share | 0.13 | 0.13 | (0.23) | 0.35 |
| Diluted | ||||
| Continuing operations | 0.09 | 0.15 | 0.25 | 0.36 |
| Discontinued operations | 0.03 | (0.03) | (0.44) | (0.03) |
| Net earnings (loss) per Common Share | $ 0.12 | $ 0.12 | $ (0.19) | $ 0.33 |
| Provider [Member] | ||||
| Revenue: | ||||
| Revenue from contract with customers | $ 122,811 | $ 118,179 | $ 360,415 | $ 345,253 |
| Cost of revenue: | ||||
| Total cost of revenue | 57,252 | 61,606 | 172,595 | 180,566 |
| Payer & Life Sciences [Member] | ||||
| Revenue: | ||||
| Revenue from contract with customers | 29,111 | 26,489 | 85,077 | 74,273 |
| Cost of revenue: | ||||
| Total cost of revenue | $ 11,234 | $ 13,422 | $ 36,498 | $ 37,984 |
MDRX Balance Sheet
2022-09-30CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 492,597 | $ 132,517 |
| Restricted cash | 1,307 | 1,308 |
| Accounts receivable, net of allowance of $12,868 and $13,360 as of September 30, 2022 and December 31, 2021, respectively | 169,029 | 171,622 |
| Contract assets, net of allowance of $564 and $576 as of September 30, 2022 and December 31, 2021, respectively | 65,453 | 63,429 |
| Prepaid expenses and other current assets | 74,384 | 60,511 |
| Assets held for sale | 8,000 | 331,955 |
| Total current assets attributable to discontinued operations | 810,770 | 761,342 |
| Fixed assets, net | 11,713 | 9,819 |
| Software development costs, net | 78,103 | 74,688 |
| Intangible assets, net | 145,255 | 149,690 |
| Goodwill | 523,927 | 506,607 |
| Deferred taxes, net | 6 | 0 |
| Contract assets - long-term, net of allowance of $1,201 and $1,534 as of September 30, 2022 and December 31, 2021, respectively | 27,957 | 28,174 |
| Right-of-use assets - operating leases | 14,520 | 18,324 |
| Other assets | 78,408 | 83,429 |
| Long-term assets attributable to discontinued operations | 0 | 793,156 |
| Total assets | 1,690,659 | 2,425,229 |
| Current liabilities: | ||
| Accounts payable | 12,609 | 5,281 |
| Accrued expenses | 82,917 | 54,518 |
| Accrued compensation and benefits | 33,857 | 31,055 |
| Deferred revenue | 98,930 | 120,748 |
| Current operating lease liabilities | 6,166 | 6,133 |
| Current liabilities attributable to discontinued operations | 18,612 | 329,347 |
| Total current liabilities attributable to discontinued operations | 253,091 | 547,082 |
| Long-term debt | 200,326 | 350,062 |
| Deferred revenue | 3,060 | 1,839 |
| Deferred taxes, net | 8,082 | 16,625 |
| Long-term operating lease liabilities | 12,315 | 16,754 |
| Other liabilities | 36,762 | 33,823 |
| Long-term liabilities attributable to discontinued operations | 0 | 50,906 |
| Total liabilities | 513,636 | 1,017,091 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of September 30, 2022 and December 31, 2021 | 0 | 0 |
| Common stock: $0.01 par value, 349,000 shares authorized as of September 30, 2022 and December 31, 2021; 279,600 and 109,260 shares issued and outstanding as of September 30, 2022, respectively; 276,705 and 116,114 shares issued and outstanding as of December 31, 2021, respectively | 2,794 | 2,766 |
| Treasury stock: at cost, 170,340 and 160,591 shares as of September 30, 2022 and December 31, 2021, respectively | (1,498,836) | (1,321,805) |
| Additional paid-in capital | 1,923,559 | 1,962,386 |
| Retained earnings | 753,392 | 767,556 |
| Accumulated other comprehensive loss | (3,886) | (2,765) |
| Total stockholders’ equity | 1,177,023 | 1,408,138 |
| Total liabilities and stockholders’ equity | $ 1,690,659 | $ 2,425,229 |
Allscripts Healthcare Solutions, Inc., together with its subsidiaries, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. Allscripts Healthcare Solutions, Inc. was founded in 1986 and is headquartered in Chicago, Illinois.